SEC Form 4

FORM 4	4
--------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response: 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Venrock Healthcare Capital Partners III, L.P. (Last) (First) (Middle) C/O VENROCK						2. Issuer Name and Ticker or Trading Symbol <u>Unum Therapeutics Inc.</u> [UMRX] 3. Date of Earliest Transaction (Month/Day/Year) 08/14/2020								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify below) below)					
7 BRYANT PARK, 23RD FLOOR (Street) NEW YORK NY 10018				4. If .	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	Form filed by One Reporting Person						
(City)	(St	ate) (Z	Zip)																
		Table	I - No	n-Deriva	tive	Secu	rities	Acc	quired	, Dis	sposed of	, or E	ene	ficially	y Own	ed			
1. Title of	Security (Ins	tr. 3)	- 1	2. Transact Date (Month/Day		Execu if any	A. Deemed xecution Date, any /onth/Day/Year)		Transaction		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Securi Benefi Owned		ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	irect direct	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) (D)	or F	Price	Report Transa (Instr. 3	ction(s)	on(s)		(Instr. 4)
Common	Stock			08/14/2	020			Р		100,000(1)) A		\$2.3	4,004,273		I		By funds ⁽²⁾⁽³⁾	
Common	Stock			08/17/2	020)20			Р		250,000 ⁽⁴⁾	A		\$2.57 4,		54,273	Ι		By funds ⁽³⁾⁽⁵⁾
Common	Common Stock 08/18/20			020			Р		101,000(6)) A		\$2.62	4,355,273		i5,273 I		By funds ⁽³⁾⁽⁷⁾		
		Tal									osed of, o				Ownee	d			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8) Solution Code (Instr. 5. Number Derivative Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amo or Num of Shar	nber					
		Reporting Person*			<u>.</u>			1								1	I		
Venroc	<u>k Healtho</u>	<u>care Capital P</u>	artner	<u>'s III, L.</u>	<u>P.</u>	_													
(Last) (First) (Middle) C/O VENROCK																			
7 BRYANT PARK, 23RD FLOOR																			
(Street) NEW YORK NY 10018																			
(City) (State) (Zip)																			
1. Name and Address of Reporting Person [*] Venrock Healthcare Capital Partners II, L.P.																			
(Last) (First) (Middle)																			
		23RD FLOOR																	
(Street) NEW Y	ORK	NY	100	018															
(City)		(State)	(Zip)															

1. Name and Address <u>VHCP Co-Inv</u>	of Reporting Person [*] estment Holding	<u>s II, LLC</u>
(Last) C/O VENROCK	(First)	(Middle)
7 BRYANT PARE	K, 23RD FLOOR	
(Street) NEW YORK	NY	10018
(City)	(State)	(Zip)
	of Reporting Person [*] estment Holding	<u>s III, LLC</u>
(Last) C/O VENROCK	(First)	(Middle)
7 BRYANT PARE	K, 23RD FLOOR	
(Street) NEW YORK	NY	10018
(City)	(State)	(Zip)
1. Name and Address <u>VHCP Manage</u>		
(Last) C/O VENROCK	(First)	(Middle)
7 BRYANT PARE	K, 23RD FLOOR	
(Street) NEW YORK	NY	10018
(City)	(State)	(Zip)
1. Name and Address <u>VHCP Manage</u>	of Reporting Person [*] ement III, LLC	
(Last) C/O VENROCK	(First)	(Middle)
7 BRYANT PARE	K, 23RD FLOOR	
(Street) NEW YORK	NY	10018
(City)	(State)	(Zip)
1. Name and Address <u>Koh Bong Y</u>	of Reporting Person [*]	
(Last) C/O VENROCK	(First)	(Middle)
7 BRYANT PARE	K, 23RD FLOOR	
(Street) NEW YORK	NY	10018
(City)	(State)	(Zip)
1. Name and Address Shah Nimish F	of Reporting Person [*]	
(Last) C/O VENROCK	(First)	(Middle)
7 BRYANT PARF	K, 23RD FLOOR	
(Street)	NY	10018
NEW YORK	N1	

(City) (State) (Zip)

Explanation of Responses:

1. Consists of (i) 26,430 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 10,710 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 57,150 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 5,710 shares purchased by VHCP Co-Investment Holdings III, LLC.

2. Consists of (i) 1,058,331 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 428,853 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,288,445 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 228,644 shares owned by VHCP Co-Investment Holdings III, LLC.

3. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Associates II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the voting members of VHCPM2 and VHCPM3. Each of VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares, but each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their respective pecuniary interests therein.

4. Consists of (i) 66,075 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 26,775 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 142,875 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 14,275 shares purchased by VHCP Co-Investment Holdings III, LLC.

5. Consists of (i) 1,124,406 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 455,628 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,431,320 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 242,919 shares owned by VHCP Co-Investment Holdings III, LLC.

6. Consists of (i) 26,694 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 10,817 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 57,722 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 5,767 shares purchased by VHCP Co-Investment Holdings III, LLC;

7. Consists of (i) 1,151,100 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 466,445 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,489,042 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 248,686 shares owned by VHCP Co-Investment Holdings III, LLC.

Remarks:

/s/ David L. Stepp, Authorized Signatory	<u>08/18/2020</u>
<u>David L. Stepp, Authorized</u> <u>Signatory</u>	<u>08/18/2020</u>
David L. Stepp, Authorized Signatory	<u>08/18/2020</u>
David L. Stepp, Attorney-in- fact	<u>08/18/2020</u>
David L. Stepp, Attorney-in- fact	<u>08/18/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.